Literature DB >> 19215691

The use of local 17beta-oestradiol treatment for improving vaginal symptoms associated with post-menopausal oestrogen deficiency.

A E Yumru1, M Bozkurt, E Inci Coşkun, G Baykan.   

Abstract

The effects of local 17beta-oestradiol therapy on the vaginal mucosa and endometrial thickness were studied in 35 post-menopausal women with symptoms of vaginal atrophy. Signs and symptoms of vaginal atrophy were measured by anamnesis, visual examination and the maturation index before and after 12 weeks' treatment with 17beta-oestradiol in the form of vaginal tablets. The maturation proportion on vaginal smear, endometrial thickness on transvaginal ultrasonography and plasma concentrations of follicle-stimulating hormone, luteinizing hormone and oestradiol were also determined. All vaginal atrophy signs and symptoms significantly improved and there was a significant increase in vaginal smear maturation with 17beta-oestradiol treatment. Endometrial thickness did not change significantly. It is concluded that 17beta-oestradiol improves the signs and symptoms of vaginal atrophy without causing endometrial stimulation and offers a safe and effective alternative to systemic hormone replacement therapy for the treatment of vaginal symptoms associated with post-menopausal oestrogen deficiency.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19215691     DOI: 10.1177/147323000903700124

Source DB:  PubMed          Journal:  J Int Med Res        ISSN: 0300-0605            Impact factor:   1.671


  3 in total

1.  The dietary ingredient, genistein, stimulates cathelicidin antimicrobial peptide expression through a novel S1P-dependent mechanism.

Authors:  Kyungho Park; Young-Il Kim; Kyong-Oh Shin; Ho Seong Seo; Jong Youl Kim; Taj Mann; Yuko Oda; Yong-Moon Lee; Walter M Holleran; Peter M Elias; Yoshikazu Uchida
Journal:  J Nutr Biochem       Date:  2014-03-27       Impact factor: 6.048

Review 2.  Assessment of vaginal atrophy: a review.

Authors:  M A Weber; J Limpens; J P W R Roovers
Journal:  Int Urogynecol J       Date:  2014-07-22       Impact factor: 2.894

3.  Endometrial safety of low-dose vaginal estrogens in menopausal women: a systematic evidence review.

Authors:  Ginger D Constantine; Shelli Graham; Kate Lapane; Kathleen Ohleth; Brian Bernick; James Liu; Sebastian Mirkin
Journal:  Menopause       Date:  2019-07       Impact factor: 2.953

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.